Key Highlights

  • The board declared a $0.24 Dividend on August 28, payable on or about October 30 to September 30 record holders.
  • Second-quarter net sales were $2.177 billion, up 4.8% reported, 4.7% in constant currency and 4.0% on an organic basis.
  • GAAP diluted EPS was $1.03, up 33.8%, and adjusted diluted EPS, a non-GAAP measure, was $2.07, flat year over year.
  • The company raised its 2026 adjusted diluted EPS guidance to $8.47-$8.59 from a prior range of $8.40-$8.55.

Overview

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) declared a quarterly dividend of $0.24 per share on August 28, 2026, payable on or about October 30 to stockholders of record on September 30. The dividend yields 1.05%. Second-quarter GAAP diluted EPS was $1.03 and adjusted diluted EPS, a non-GAAP measure, was $2.07.

Dividend Program and Shareholder Returns

The board approved a quarterly Cash Dividend of $0.24 per share for the third quarter of 2026 on August 28. It is payable on or about October 30 to stockholders of record on September 30, and the stock trades ex-dividend on September 30.

The second-quarter dividend was also $0.24 per share, declared May 22, 2026, with a June 25 Record Date and payment on or about July 31. In the first half of 2026 the company paid $93.4 million in dividends and repurchased $500.8 million of its shares.

About the Company

Zimmer Biomet Holdings, Inc. is a global medical technology company based in Warsaw, Indiana. Chief Executive Officer Ivan Tornos leads the company. It reports GAAP results alongside adjusted measures that it identifies as non-GAAP.

Second-Quarter Sales and Earnings

Net sales were $2.177 billion, up 4.8% on a reported basis, up 4.7% in constant currency and up 4.0% on an organic constant currency basis. For the first half, net sales were $4.264 billion, up 7.0% reported and 3.4% organically.

GAAP diluted EPS was $1.03, up 33.8%, and GAAP net Earnings were $198.3 million. Adjusted diluted EPS, a non-GAAP measure, was $2.07, flat year over year, and adjusted net earnings were $399.6 million.

For the first half, GAAP diluted EPS was $2.25, up 33.9%, and adjusted diluted EPS was $4.16, up 7.2%. GAAP net earnings were $436.5 million and adjusted net earnings were $809.0 million.

Cash Flow and Updated 2026 Guidance

Operating Cash Flow for the first half was $807.2 million. The company repurchased $500.8 million of shares and paid $93.4 million in dividends during the same period.

The company raised its 2026 guidance. Reported Revenue growth is now 3.9% to 4.9%, compared with a prior range of 2.5% to 4.5%. Constant currency growth is 3.4% to 4.4%, compared with 2.0% to 4.0%, and organic constant currency growth is 2.25% to 3.25%, compared with 1.0% to 3.0%.

Adjusted diluted EPS guidance, a non-GAAP measure, is $8.47 to $8.59, compared with a prior range of $8.40 to $8.55. Tornos said the company delivered solid top-line and bottom-line performance in the quarter and cited healthy underlying markets and continued momentum from its innovation cycle.

Outlook

The gap between GAAP and adjusted EPS, organic constant currency growth, the raised guidance ranges, share repurchases and the board's quarterly declarations are the relevant considerations. The second quarter is the most recent reported period, and the August declaration is the latest dividend action.